25758270
BACKGROUND	Despite great reduction of in-stent restenosis , first-generation drug-eluting stents ( DESs ) have increased the risk of late stent thrombosis due to delayed endothelialization .
BACKGROUND	Arsenic trioxide , a natural substance that could inhibit cell proliferation and induce cell apoptosis , seems to be a promising surrogate of sirolimus to improve DES performance .
BACKGROUND	This randomized controlled trial was to evaluate the efficacy and safety of a novel arsenic trioxide-eluting stent ( AES ) , compared with traditional sirolimus-eluting stent ( SES ) .
METHODS	Patients with symptoms of angina pectoris were enrolled and randomized to AES or SES group .
METHODS	The primary endpoint was target vessel failure ( TVF ) , and the second endpoint includes rates of all-cause death , cardiac death or myocardial infarction , target lesion revascularization ( TLR ) by telephone visit and late luminal loss ( LLL ) at 9-month by angiographic follow-up .
RESULTS	From July 2007 to 2009 , 212 patients were enrolled and randomized 1:1 to receive either AES or SES .
RESULTS	At 2 years of follow-up , TVF rate was similar between AES and SES group ( 6.67 % vs. 5.83 % , P = 0.980 ) .
RESULTS	Frequency of all-cause death was significantly lower in AES group ( 0 vs. 4.85 % , P = 0.028 ) .
RESULTS	There was no significant difference between AES and SES in frequency of TLR and in-stent restenosis , but greater in-stent LLL was observed for AES group ( 0.29 0.52 mm vs. 0.10 0.25 mm , P = 0.008 ) .
CONCLUSIONS	After 2 years of follow-up , AES demonstrated comparable efficacy and safety to SES for the treatment of de novo coronary artery lesions .

